CI

At a glance

ClinicalIndex Comparison Record
Phase 4Terminated· 782 enrolled
Drug / intervention
Abrupt Clopidogrel Interruption +1 moredrug
Likely dose
Abrupt Clopidogrel Interruption 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00640679
NCT00640679Phase 4Terminated
Terminated
CompareCT.gov

Prospective, Randomized, Double-Blind Trial of Abrupt and Tapered Interruption of Long-term Clopidogrel Therapy After Implantation of a Drug-Eluting Stent

Deutsches Herzzentrum Muenchen·interventional·Posted Mar 21, 2008·Updated Jul 27, 2016

In Brief

A Phase 4 clinical trial evaluating Abrupt Clopidogrel Interruption and Clopidogrel Tapering for Coronary Artery Disease. Terminated early, enrolled 782 participants across 2 sites.

Signals

Trial was terminated early

Detailed Summary

The hypothesis to be tested is that gradual clopidogrel therapy cessation is associated with a superior clinical outcome compared with abrupt cessation (superiority hypothesis).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesGermany
Collaborators--

Timeline

Phase 4TerminatedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2008
Enrollment StartApr 1, 2008
Primary CompletionAug 1, 2012
TodayJul 1, 2026
Enrollment to primary: 4.3 yearsPosted 18.3 years ago

Interventions

Abrupt Clopidogrel Interruptiondrug

Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.

Clopidogrel Taperingdrug

Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.